The FDA Presents Its Case for Targeting Talc
Your editorial 'The FDA Takes a Trial-Lawyer Turn' (May 21) criticizes the Food and Drug Administration for convening an expert panel to explore whether talc is a potential carcinogen. You cite three studies that don't support that proposition but omit the 2019 review of 30 studies that found a strong association between talc and cancer. Last year the International Agency for Research on Cancer also found that the mineral is 'probably carcinogenic to humans,' citing strong mechanistic evidence. At a recent FDA expert panel, one pathologist reported that talc particles have been observed in cancer cells.
For these reasons, talc has been removed from baby powder, but remarkably children continue to eat it in candy and other foods. Millions of Americans also consume it in medications. Talc is used as a lubricant that allows for easier mass production of pills, food and cosmetics. As one scientist informed our panel, safe, low-cost alternatives exist.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
16 minutes ago
- Fox News
Cuomo attacked during debate by fellow Dems for allegedly lying to Congress about COVID nursing home scandal
Former New York Gov. Andrew Cuomo was blasted by fellow Democrats running against him to be the next mayor of New York City for lying to Congress, an allegation pushed by Republicans that the Trump administration is currently investigating. Cuomo repeatedly dismissed questions throughout Wednesday night's debate on whether he lied to Congress about his role in drafting a New York State Department of Health report that officials determined had undercounted the number of nursing home deaths during the COVID-19 pandemic. Instead, Cuomo blasted the current investigation as a symptom of partisan politics and insisted the report in question "did not undercount the deaths." "The people died and he still won't answer your questions," Cuomo's opponent, Michael Blake, a former state assemblyman from the Bronx, said after Cuomo failed to provide a straight answer. Blake's retort resulted in one of the debate moderators asking Cuomo once again to respond to the allegations that he lied to Congress about his role in drafting the report that undercounted the number of COVID-19 nursing home deaths. This time, he engaged. "No, I told Congress the truth," Cuomo relented. "No, we did not undercount any deaths," he added. "When they are all counted, we're number 38 out of 50, which I think, shows that compared to what other states went through, we had it first and worst, and that only 12 states had a lower rate of death – we should really be thanking the women and men who worked on those things." "It's just a yes or no question," the moderator shot back at Cuomo. "Were you involved in the producing of that report?" However, Cuomo still did not address the question directly, leading to laughter from his opponents. "It's not only that Andrew Cuomo lied to Congress – which is perjury – he also lied to the grieving families whose loved ones he sent in to those nursing homes to protect his $5 million book deal," said Brad Lander, New York City's comptroller. "That's corruption." Last month, the Trump administration's Department of Justice opened a criminal investigation to get to the bottom of whether Cuomo lied to Congress about the decisions he made during the COVID-19 pandemic while serving as governor. In March 2020, Cuomo issued a directive that initially barred nursing homes from refusing to accept patients who had tested positive for COVID-19. The directive was meant to free up beds for overwhelmed hospitals, but more than 9,000 recovering coronavirus patients were ultimately released from hospitals into nursing homes under the directive, which was later rescinded amid speculation that it had accelerated outbreaks. Subsequently, a report released in March 2022 by the New York state comptroller found Cuomo's Health Department "was not transparent in its reporting of COVID-19 deaths in nursing homes" and it "understated the number of deaths at nursing homes by as much as 50%" during some points of the pandemic. New York Attorney General Letitia James similarly released a report amid the pandemic showing New York state nursing home deaths had been undercounted.
Time Business News
17 minutes ago
- Time Business News
When to Choose Strattera Over Adderall
Attention-Deficit/Hyperactivity Disorder (ADHD) affects millions of people worldwide, leading to difficulties with focus, impulsivity, and hyperactivity. While stimulant medications like Adderall are often the first line of treatment, non-stimulant options such as Strattera (atomoxetine) can be a more appropriate choice in certain situations. Understanding when to choose strattera vs adderall involves evaluating factors such as the patient's medical history, potential side effects, risk of substance abuse, and overall treatment goals. When managing depression and anxiety, selecting the appropriate medication is crucial for effective treatment. Both medications in question are popular SSRIs that help balance serotonin levels in the brain, improving mood and emotional stability. In the middle of this discussion, Lexapro vs zoloft often arises as a common comparison due to their similar uses but distinct side effect profiles and dosing schedules. While some patients respond better to one, others may experience fewer adverse effects or more rapid relief with the alternative. Consulting a healthcare provider is essential to tailor the choice to individual needs and medical history. Strattera and Adderall are both approved by the FDA for treating ADHD but function in very different ways. Adderall is a stimulant composed of amphetamine salts that work by increasing the levels of dopamine and norepinephrine in the brain. This results in improved attention, reduced impulsivity, and greater overall concentration. On the other hand, Strattera is a selective norepinephrine reuptake inhibitor (NRI), which means it primarily boosts norepinephrine without significantly impacting dopamine levels. Unlike Adderall, Strattera is not a controlled substance and carries a much lower risk of abuse. One of the primary reasons to choose Strattera over Adderall is when there's a concern about substance misuse or a history of addiction. Adderall is a Schedule II controlled substance due to its high potential for abuse and dependency. For individuals with a history of substance use disorder, Adderall may pose a serious risk. Strattera, being non-stimulant and non-addictive, offers a safer alternative. It allows for effective ADHD management without the risk of reinforcing addictive behaviors, making it particularly useful in populations vulnerable to stimulant misuse. Many individuals with ADHD also suffer from comorbid mental health conditions like anxiety or depression. In such cases, Strattera may be a better option than Adderall. Stimulants like Adderall can exacerbate anxiety symptoms in some patients, leading to increased restlessness, jitteriness, or panic attacks. Strattera, on the other hand, has shown some efficacy in improving symptoms of anxiety and may also provide mild antidepressant effects due to its norepinephrine-enhancing properties. Choosing Strattera can help manage both ADHD and accompanying mood or anxiety disorders without worsening either condition. Adderall, especially the immediate-release version, has a relatively short duration of action, requiring multiple doses throughout the day. Even the extended-release versions may wear off by late afternoon or evening. In contrast, Strattera is taken once daily and offers 24-hour symptom coverage. This can be particularly advantageous for individuals who need consistent control over their ADHD symptoms throughout the day and into the evening. Students, working professionals, or parents managing multiple responsibilities might find this steady effect preferable to the peaks and troughs associated with stimulant medications. While stimulants are effective for many people, they also come with a host of potential side effects, including insomnia, appetite suppression, irritability, increased heart rate, and elevated blood pressure. For some individuals, these side effects can be intolerable or even dangerous, particularly if they have underlying cardiovascular issues. Strattera generally has a milder side effect profile and is not associated with the same degree of appetite suppression or cardiovascular stimulation. Although it has its own set of side effects, such as nausea or fatigue, these are often more manageable and tend to lessen over time. In some clinical scenarios, a non-stimulant medication like Strattera is the preferred first-line treatment. For example, in younger children (especially those under six years of age), stimulants may not be recommended due to potential side effects and lack of data on long-term safety. Pediatricians may opt for Strattera as a gentler initial approach. Additionally, parents who are concerned about the stigma or potential long-term effects of stimulant use may feel more comfortable starting their child on a non-stimulant option. Stimulants such as Adderall can interfere with sleep, especially if taken later in the day. Sleep disturbances are a common complaint among stimulant users and can contribute to irritability, mood swings, and worsening of ADHD symptoms. Strattera is less likely to cause sleep disruption and may even help improve sleep quality for some patients. For individuals who already struggle with insomnia or erratic sleep patterns, Strattera may be the better treatment choice. One of the key differences between Adderall and Strattera is how quickly they take effect. Adderall typically produces noticeable results within hours, making it ideal for patients seeking immediate symptom relief. Strattera, however, requires several days to weeks to build up in the system and reach full therapeutic effect. For patients and clinicians willing to adopt a slower, more gradual treatment approach, this delayed onset can be worthwhile, especially given Strattera's longer-term stability and lower side effect profile. Because Adderall is a controlled substance, it comes with regulatory burdens such as limited refills, stricter prescribing rules, and potential stigma. Some patients or caregivers may prefer a treatment that does not involve these complications. Strattera, being non-controlled, can be prescribed more freely and refilled more easily. This can improve medication adherence and reduce the hassle associated with frequent doctor visits or pharmacy restrictions. In some cases, clinicians may not be completely certain whether a patient's symptoms are primarily due to ADHD or another condition such as anxiety, depression, or trauma-related disorders. Since stimulants can exacerbate certain psychiatric symptoms or produce euphoria, starting with a non-stimulant like Strattera can be a safer way to assess a patient's response without clouding the diagnostic picture. If symptoms improve with Strattera, it may confirm that norepinephrine imbalance plays a role in the condition, guiding future treatment decisions. Choosing between Strattera and Adderall requires a personalized approach that considers the individual's medical history, lifestyle, comorbid conditions, and treatment preferences. While Adderall remains highly effective for many, Strattera presents a viable and often safer alternative for those with substance abuse risks, anxiety, sleep disturbances, or cardiovascular concerns. It is also a strong option for patients seeking all-day symptom coverage or those who prefer to avoid controlled substances. Consulting with a knowledgeable healthcare provider is crucial in determining which medication best aligns with the patient's needs and long-term goals. TIME BUSINESS NEWS
New York Times
17 minutes ago
- New York Times
Trump's Travel Ban Could Shake Up International Sporting Events
The proclamation President Trump's signed this week banning travel to the United States by people from a dozen countries makes an exception for athletes, coaches and support staff for 'major sporting events,' including the World Cup and the Olympics. What qualifies as a major sporting event remains to be seen. Mr. Trump's proclamation declaring the ban, issued on Wednesday, says that the secretary of state, Marco Rubio, will determine which events can receive an exemption. A host of international sporting events are planned in the United States over the next months and years. While some of the countries on the ban list, like Chad and Yemen, are not traditional sporting powers, others, like Iran and Haiti, could well expect to send athletes to the United States for a range of competitions. Mr. Trump also imposed a lower level of restrictions on seven other countries, including Cuba, a strong player on the international sporting stage, and Venezuela. Decisions will have to be made quickly. The CONCACAF Gold Cup, the men's soccer championship for North American, Central American and Caribbean nations, begins June 14 and will be played at sites across the United States (and one in Canada). Haiti has qualified for the competition and is scheduled to play games in San Diego, Houston and Arlington, Texas. The Club World Cup, the world championship for men's club soccer teams, also begins June 14 in several U.S. cities. No team based in a country on the banned list has qualified, but the teams involved include players and staff members from all over the world. CONCACAF, which runs the Gold Cup, and FIFA, which runs the Club World Cup, did not immediately respond to requests for comment. Other events coming to the United States this year — including the under-19 softball World Cup and the world skateboarding championships — are less likely to be considered 'major' events. There are also big races, like the Chicago and New York marathons in the fall. Mr. Rubio may find himself facing a lot of judgment calls. The implications for college athletics, where rosters in many sports are dotted with international students, are also unclear. Both events that are explicitly exempted from the ban — the men's soccer World Cup and the Summer Olympics — are coming to the United States after this year. The World Cup is scheduled for 2026, and Iran has already qualified. (Hosting duties will be shared with Canada and Mexico.) Los Angeles will host the Summer Olympics in 2028.
